Orum Therapeutics closed a ₩146 billion (≈$100 million) financing to advance its platform of degrader‑antibody conjugates, a hybrid that marries targeted antibodies with protein‑degradation payloads instead of cytotoxins. The company said proceeds will accelerate ORM‑1153, a CD123‑targeting candidate for acute myeloid leukemia, toward clinical entry. Orum shelved an earlier HER2 program after hepatotoxicity signals but said the platform remains viable and that the new funds will back its AML strategy and collaborations with Bristol Myers Squibb and Vertex. Management highlighted the need for novel payload classes to address ADC resistance in hematologic malignancies. Investors will watch the company’s IND timelines and early safety readouts closely; the funding round signals sustained investor appetite for next‑generation ADC modalities despite recent ADC safety headlines.